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Between 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy 
and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in 
the Yoro Department, Honduras. A total of 24,471 children were screened for Trypanosoma cruzi IgG antibodies 
through conventional enzyme-linked immunosorbent assays (ELISA) on filter paper. Recombinant ELISA (0.93% se-
roprevalence) showed 256 initially reactive cases, including 232 confirmed positive cases. Of these, 231 individuals 
were treated with benznidazole (7.5 mg/kg/day) for 60 days and were followed with a strict weekly medical control 
and follow-up protocol. At the end of the project, 229 patients were examined by the Honduras Secretariat of Health 
for post-treatment serological assessments; 88.2% seroconverted after 18 months and 93.9% seroconverted after 
three years. No differences were found in the seroconversion rates according to age or sex. Most of the side effects 
of the treatment were minor. These results support the argument that in areas where T. cruzi I is predominant and 
in areas affected by T. cruzi II, when vector transmission has been interrupted, Chagas disease diagnosis and treat-
ment are feasible, necessary and ethically indisputable.
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In the past 15 years, the burden of Chagas disease 
(also known as American trypanosomiasis) has signifi-
cantly decreased as a result of a number of multinational 
regional  initiatives  promoted  and  coordinated  by  the 
Pan American Health Organisation (PAHO). According 
to recent estimates and information from 21 countries 
where the disease is endemic, 8-9 million people are in-
fected by the Trypanosoma cruzi parasite and around 40 
million are at risk of becoming infected (PAHO 2006, 
Scofield et al. 2006). These estimates are 50% lower 
than the infection rate in 1990. However, Chagas dis-
ease continues to have a considerable impact on public 
health in the Americas and around 200,000 new cases 
and 20,000 deaths occur every year (WHO 2005, Mon-
cayo & Ortiz-Yanine 2006).
After the disease was discovered by Carlos Chagas in 
Brazil in 1909, human cases were reported in El Salvador 
in Central America in 1913 (Segovia 1913). In Hondu-
ras, Chagas disease has been known since 1960, but the 
first nationwide sero-epidemiological and entomological 
studies were not carried out until the 1970s and 1980s. 
These studies showed the presence of two main vectors 
(Rhodnius prolixus and Triatoma dimidiata) related to 
housing conditions and showed the seroprevalence of T. 
cruzi in different areas of the country. Approximately 
300,000 people are infected and this estimate includes 
a 6% rate of seroprevalence of T. cruzi infection among 
the overall population and a 3% rate among schoolchil-
dren in rural areas. These rates are mostly linked to vec-
tor transmission (República de Honduras 2003a, 2004, 
Yamagata & Nakagawa 2006).
The Honduras Secretariat of Health (HSH) is focused 
on  controlling  this  pathogen  and,  within  the  Central 
American Initiative for Chagas Disease Control frame-
work, initiated the 2003-2007 National Strategic Plan for 
the Prevention and Control of Chagas Disease. This plan 
included technical support from the PAHO/WHO and 
broad national and international multi-sector participa-
tion (República de Honduras 2003a, b, Ponce 2007). One 
of the main objectives of the plan was to scale up diag-
nostic and treatment coverage. With this goal in mind, 
Médécins Sans Frontières-Spain (MSF-E) collaborated 
with the HSH to develop a comprehensive strategy to 
combat  Chagas  disease  that  included  vector  control 
activities (such as spraying with residual insecticides), 
community-based  education,  the  training  of  medical 
staff, diagnosis and etiological treatment with benznida-
zole. In addition, the efficacy and safety of benznidazole 
in asymptomatic infected children was assessed.
PATIENTS, MATERIALS AND METHODS
Study area and patients - This project was imple-
mented  between  July  1999-December  2002  in  Yoro 
Department, Honduras, located in the country’s central 
mountainous area where the infection is endemic and 
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endemic area where interrupted vector transmission was 
under  surveillance,  high  seroprevalence  rates  existed 
and teams with the operational capacity to provide and 
supervise treatment were available.
Asymptomatic infected children under the age of 13 
years were included in the study. Individuals with se-
vere malnutrition, anaemia or other underlying diseases 
were excluded from the study and, depending on the se-
verity of these conditions, were referred to the Primary 
Health Care Units or to the rural area hospital. Between 
the end of the project and September 2005, HSH was 
responsible for patient treatment and for carrying out 
post-treatment serological assessments to confirm cure 
rates. The study protocol was approved by the HSH of 
the Ministry of Health and by MSF-E.
Baseline evaluation and drug management - T. cruzi 
infection was detected using serological tests with en-
zyme-linked immunosorbent assay (ELISA) with crude 
antigen (Chagatest ELISA; Wiener Lab, Rosario, Argen-
tina). The blood samples were obtained by digital punc-
ture at the Yoro Hospital and spotted on filter paper. A 
second ELISA test, prepared with recombinant T. cruzi 
antigens  (Chagatest  recombinant  ELISA,  version  3.0; 
Wiener Lab, Rosario, Argentina), was performed using 
an ELISA plate reader [optical density (OD) at 450 nm]. 
This second test was used to confirm the results of sam-
ples considered reactive during visual readings (ELISA 
crude antigens) and to validate 10% of those samples 
testing negative at the Central Reference Laboratory for 
Chagas disease and Leishmaniasis in Tegucigalpa.
The seropositive children started supervised treatment 
with benznidazole (Radanil®, Roche) and were given a 7.5 
mg/kg dose two times a day for 60 days. According to the 
follow-up protocol, adverse reactions were recorded and 
periodic clinical examinations were completed. In order to 
determine the treatment efficacy, two serological assess-
ments using Chagatest recombinant ELISA were conduct-
ed. The children who remained seropositive 18 months 
after chemotherapy, despite presenting a decrease in their 
antibody titres, were followed until 36 months after treat-
ment. These assessments were carried out by simultane-
ously processing the post-treatment filter paper blood sam-
ples and the pre-treatment samples preserved at -20ºC.
Informed consent - Parents or guardians of children 
registered for treatment were informed about its poten-
tial benefits and possible risks, including potential ad-
verse reactions and how to proceed if they appeared. 
Once  they  were  informed,  the  corresponding  signed 
consent was requested.
Assessment of treatment outcomes - The results were 
measured in terms of (i) negative seroconversion, de-
fined as the disappearance of antibodies to T. cruzi, (ii) 
tendency to seroconvert, defined as a ≥ 75% reduction in 
OD readings for serological tests compared to baseline 
values (equivalent to a decrease of ≥ 2 dilutions of anti-
body titres) and (iii) average reduction of antibody titres 
after the treatment on repeated serological tests.
Statistical analysis - Normalised differences in anti-
body titres were calculated in consecutive assessments 
and comparisons to pre-treatment baseline values were 
made with the following equation: [(final antibody titres 
-  initial  antibody  titres)/initial  antibody  titres]  x  100. 
Likewise,  differences  between  the  baseline  and  post-
treatment T. cruzi median antibody titres were compared 
using  the  Wilcoxon  ranked  sum  test.  Seroconversion 
rates at 18 and 36 months after treatment were compared 
using  the  McNemar  test.  Mann-Whitney  U-test  and 
Kruskal-Wallis test were used to compare differences in 
T. cruzi antibody titres according to age and sex, while 
Chi-square or Fisher’s exact tests were used to compare 
differences in seroconversion rates. The statistical sig-
nificance was set at 5%.
RESULTS
Screened subjects and seropositive cases - A total of 
24,771 children out of a census of 25,563 (96.9% cover-
age) were screened. The children lived in five munici-
palities in the Yoro Department and ranged in age from 
nine months to 12 years; 15,746 (64%) were under the age 
of five years and 9,025 (36%) were between 5-12 years 
of age. Two hundred and fifty six cases were initially 
found to be reactive by the conventional ELISA (crude 
antigens), including 232 cases that were confirmed to be 
positive with the Chagatest recombinant ELISA (0.93% 
seroprevalence). Of these serologically-positive children, 
65 (28.1%) were under the age of five years; 196 (84.5%) 
lived in localities previously infested with R. prolixus 
and 36 (15.5%) lived in areas previously infested with T. 
dimidiata. The median time between spraying and the 
onset of treatment was eight months (interquartile range 
4-12.5 months). Nearly all of the cases were detected 
in asymptomatic children in the indeterminate or early 
chronic phase of Chagas disease; the exception was an 
acute case which presented with Romaña’s sign.
Treated patients and follow-up - A total of 231 se-
ropositive children started the treatment. Of these, 229 
patients (99.1%) were followed for at least 18 months 
and a subset of 27 patients were monitored for up to 36 
months after treatment. Three children failed to com-
plete the 60-day therapeutic protocol, but were treated 
for almost a full course (43, 49 and 50 days of treat-
ment), and one case of acute Chagas disease was treated 
for 30 days. These four patients had seroconverted by 
the 18 month follow-up.
Adverse events - Unwanted effects were frequently 
observed during the treatment; most side effects were 
minor or moderate and most did not require the discon-
tinuation of medication. Only three patients interrupted 
the treatment within seven weeks due to severe unwanted 
neurological effects (peripheral neuropathy of the lower 
limbs). The most common adverse effects were gastro-
intestinal disorders (n = 62 cases, 26.8% of the total), 
followed  by  dermatological  conditions  (n  =  30,  13%) 
and neurological problems (n = 24, 10.4%) (Table I).   
No significant differences were seen in the proportion 
of adverse effects according to age or sex. The most fre-
quent adverse gastrointestinal episodes included epigas-
tralgia and/or abdominal pain (n = 42 episodes), nausea 
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(n = 5) and hepatitis (n = 1); these mostly appeared dur-
ing the first week after treatment. Dermatological con-
ditions included local or widespread pruritus (n = 33), 
more or less widespread maculopapular exanthema (n 
= 12) and urticaria (n = 1); these conditions more fre-
quently occurred 2-3 weeks after treatment began. The 
most common neurological problems include peripheral 
polyneuritis (n = 6), headaches (n = 5), arthromyalgia in 
the lower limbs (n = 4) and seizures (n = 2). No deaths 
occurred during treatment and no hospitalisations oc-
curred due to benznidazole-related adverse events.
Serological outcomes - Post-therapeutic serological 
results are shown in Tables II, III and IV. Quantitative 
analysis of changes in the antibody titres confirmed sig-
nificant global differences in both the first (Table II) and 
second assessments (Table III).
After 18 months, the overall seroconversion rate was 
88.2% (95% CI from 84-92.4%); it increased to 93.9% 
(95% CI from 90.8-97%) at the end of the three-year fol-
low-up, although this increase was not statistically signifi-
cant (Table IV). Thirteen out of the 27 cases (48.1%) that 
remained seropositive 18 months after treatment yielded 
negative  serological  results  at  36  months  after  chemo-
therapy; 19 of the 27 (70.4%) cases tended to seroconver-
sion (i.e., had OD readings that had decreased by ≥ 75%). 
These patients were mostly younger than 10 years of age 
(10/13, 76.9% and 13/19, 68.4%, respectively) (Table IV).
Two children under the age of five years did not show 
any significant variation in the antibody titres despite 
completing  the  treatment.  Their  dwellings  were  thor-
oughly checked to eliminate the possibility of reinfec-
tion. Between 1-2 months after the benznidazole treat-
ment ended they started and completed treatment with 
nifurtimox (Lampit®, Bayer) at 8 mg/kg/day for 30 days. 
Their last post-treatment serological assessments were 
done at 48 months and 51 months and although the final 
results were positive, antibody titres in both cases had 
decreased by about 40%.
Of the 229 treated patients who were monitored for 
up to 18 months post-treatment, 85.2% (95% CI from 
80.5-89.8%) had decreased OD by ≥ 75% compared to 
the baseline values. By the end of the follow-up period 
(36 months), 93.4% (95% CI from 90.2-96.7%) of pa-
tients showed a ≥ 75% reduction in OD; this difference 
was statistically significant. Nineteen out of the 34 cases 
TABLE I
Distribution of benznidazole-related side effects among patients that started treatment in Médécins Sans Frontières-Spain and 
Honduras Secretariat of Health project in Yoro, Honduras, 1999-2005 (n = 231)
Side effects
Gastrointestinal
n
Dermatological
n
Neurological
n
Total
n (%)
Age (years) < 5  18 7 7 65 (28.1)
5-9  19 10 5 71 (30.7)
≥ 10  25 13 12 95 (41.1)
Gender Male 31 14 9 105 (45.5)
Female 31 16 15 126 (54.5)
Total (%) 62 (26.8) 30 (13.0) 24 (10.4) 231
in the boxes in the same row, patients can be repeated. The same patient can have side effects of different nature.
TABLE II
Comparison of Trypanosoma cruzi antibody titres between baseline values and 18 months after treatment in Médécins Sans 
Frontières-Spain and Honduras Secretariat of Health project in Yoro, Honduras, 1999-2005 (n = 229)
n
Baseline
Median (IQR)
18 months
Median (IQR) p valuea
Age (years) < 5  65 2.14 (1.74-2.44) 0.34 (0.33-0.34) < 0.001
5-9  70 2.18 (1.68-2.51) 0.33 (0.32-0.34) < 0.001
≥ 10  94 2.26 (1.84-2.54) 0.33 (0.32-0.34) < 0.001
Gender Male 104 2.21 (1.84-2.64) 0.34 (0.33-0.34) < 0.001
Female 125 2.21 (1.74-2.46) 0.33 (0.32-0.34) < 0.001
Total  229 2.18 (1.77-2.48) 0.33 (0.32-0.34) < 0.001
 
a: p value for Wilcoxon ranked sum test; IQR: interquartil range.Etiological treatment of Chagas disease • Josep M Escribà et al. 989
(55.9%) did not have a ≥ 75% decrease in their antibody 
titres by the first assessment, but reached this percent-
age of decrease by the second assessment (McNemar test 
p < 0.001) (data not shown). No significant differences 
related to age or sex were found in the antibody titres or 
seroconversion rates (Tables II-IV).
DISCUSSION
Cost-efficacy analyses like the one carried out by 
MSF-E clearly show that vector control programmes 
that include Chagas disease treatment are much more 
effective  than  simply  isolated  vector  control.  These 
programmes have a direct influence on disease impact 
and prevalence as well as on morbidity and mortality 
(Wilson et al. 2005).
On the other hand, several controlled trials (Andrade 
et al. 1996, 2004, Coura et al. 1997, Sosa-Estani et al. 
1998) and longitudinal studies with various benznida-
zole-based regimens (Ferreira 1990, Viotti et al. 1994, 
Gallerano & Sosa 2000, Cançado 2002, Streiger et al. 
2004) that were developed in Brazil, Argentina and Chile 
in the 1990s show that trypanocide treatment is generally 
effective in children and adolescents in the chronic latent 
phase; cure rates as high as 60% have been demonstrated 
through serological negative conversion (Andrade et al. 
1996, 2004, Gallerano & Sosa 2000). Based on these re-
sults, the PAHO/WHO made an official recommenda-
tion in favour of etiological treatment for children and 
young  adults  with  the  indeterminate  form  of  chronic 
chagasic infection (PAHO/WHO 1998). The criteria for 
defining a cure in most of the quoted studies included 
ongoing negative results from conventional serological 
tests (Luquetti 1996, Cançado 1999, 2001, Coura & de 
Castro 2002, Dias 2003).
A significant percentage of adverse effects can be 
mitigated  by  carefully  monitoring  patients  with  strict 
diagnostic  and  treatment  follow-up  protocols.  In  the 
present  study,  the  intensity  and  characteristics  of  the 
observed adverse reactions did not differ substantially 
from those described by others (Villa et al. 2005, Guhl 
et al. 2008, Ponce 2008). In addition, we did not find dif-
ferences from other studies in the rate of withdrawal of 
patients due to the side effects of benznidazole (Andrade 
et al. 1996, Sosa-Stani et al. 1998).
Our  results  corroborate  the  relevance  of  mid  and 
long-term post-treatment follow-up in patients present-
TABLE III
Comparison of Trypanosoma cruzi antibody titres between 18-36 months after treatment in Médécins Sans Frontières-Spain 
and Honduras Secretariat of Health project in Yoro, Honduras, 1999-2005 (n = 27)
n
18 months
Median (IQR)
36 months
Median (IQR) p valuea
Age (years) < 5 7 1.29 (1.12-2.24) 0.33 (0.32-1.46) 0.018
5-9 9 1.16 (0.97-1.29) 0.32 (0.32-0.70) 0.008
≥ 10 11 1.14 (1.12-1.32) 0.62 (0.33-0.68) 0.003
Gender Male 15 1.24 (1.12-1.46) 0.58 (0.33-0.72) 0.001
Female 12 1.12 (0.95-1.30) 0.33 (0.31-0.64) 0.002
Total  27 1.18 (1.12-1.32) 0.33 (0.32-0.68) < 0.001
a: p value for Wilcoxon ranked sum test; IQR: interquartil range.
TABLE IV
Seroconversion rates in post-treatment serological assessments in Médécins Sans Frontières-Spain and Honduras Secretariat of 
Health project in Yoro, Honduras, 1999-2005
n
Seroconversion rate
18 months 36 months
n/% (CI 95%) na/% (CI 95%)
Age (years) < 5  65 58/89.2 (81.7-96.8) 63/96.9 (89.5-99.2)
5-9  70 61/87.1 (79.3-95.0) 66/94.3 (86.2-97.8)
≥ 10  94 83/88.3 (81.8-94.8) 86/91.5 (84.1-95.6)
Gender Male 104 89/85.6 (78.8-92.3) 96/92.3 (87.2-97.4)
Female 125 113/90.4 (85.2-95.6) 119/95.2 (91.5-98.9)
Total 229 202/88.2 (84.0-92.4) 215/93.9 (90.8-97.0)
a: numbers of seroconverted cases at 36 months are cumulative; CI: confidence interval.990 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 104(7), November 2009
ing  with  the  indeterminate  chronic  phase  of  Chagas 
disease. A significant proportion of cases that are still 
seropositive in the first assessment become negative by 
subsequent assessments, particularly in younger patients; 
in addition, we observed a high seroconversion rate in a 
relatively short period of time (3 years). Even though a 
significant percentage of patients who were followed for 
36 months after completing their treatment remained se-
ropositive (14/27, 51.9%), six patients (42.9%) did show a 
clear tendency towards seroconversion and a significant 
reduction of antibody titres in the follow-up serology.
Some limitations must be considered in the interpreta-
tion of these results: only one serological test (recombinant 
ELISA) was used to assess the cure rate, the study was 
conducted with a non-controlled observational design and 
the investigation was not able to follow all of the patients 
for up to three years after treatment. Nevertheless, the high 
specificity of the recombinant ELISA justifies its use. We 
have not used a second serological test with different prin-
ciples and antigens to verify cures, as recommended by the 
WHO, because of financial constraints, logistical compli-
cations and limited time and human resources.
In Honduras, the MSF-E designed treatment of se-
ropositive patients was an important innovation in the 
fight against Chagas disease. Initially, recommendations 
for  the  national  programme  only  focused  on  treating 
acute and congenital cases (Gergonne 2001).
Notwithstanding this fact, the supervised treatment 
of T. cruzi seropositive children has occurred in different 
ways throughout the country with community participa-
tion in an intervention area under surveillance. The first 
trial occurred between 1992-1993, when 45 children be-
tween the ages of six months and five years were treated 
in the municipality of San Marcos de Colón, Choluteca 
Department; these children reached 91.1% seroconver-
sion two years after treatment (Ponce 2008).
In 2000 and parallel with the MSF-E project, MSF-
France launched another Chagas disease comprehensive 
care programme that included etiological treatment for the 
infected population under 13 years of age in the Francisco 
Morazán and Olancho Departments. Similar programmes 
were replicated by the HSH in Intibucá, El Paraíso and 
Francisco Morazán. The same MSF-E protocols were used 
based on the recommendations made by the WHO and 
HSH. The results, based on post-treatment serological as-
sessments, showed a cure rate of 83% and 100%, respec-
tively, at 18 and 36 months after treatment (República de 
Honduras 2003a, Ponce 2008). A similar study carried out 
among schoolchildren between the ages of 4-15 years in 
Colombia in 2002-2003 (Guhl et al. 2008) revealed compa-
rable results, with 94.4% seroconversion six months after 
treatment, exceeding by far the data reported by the stud-
ies carried out in the Southern Cone in the 1990’s.
The aforementioned results coincide with our find-
ings and contrast with other studies that show serocon-
version rates of between 2.3% by two years after treat-
ment  and  65%  by  six  years  after  treatment  (Ferreira 
1990, Viotti et al. 1994, Andrade et al. 1996, 2004, Sosa-
Stani et al. 1998, Gallerano & Sosa 2000, Streiger et al. 
2004). These differences are partly ascribed to the study 
designs (observational or experimental), various follow-
up times, treatment patterns used (dose and duration), 
stages of the disease, ages of the patients and different 
serological assessment tests that were used (Coura & 
de Castro 2002). Geographical diversity also plays an 
important role in these differences. T. cruzi strains in   
Central America, as confirmed by the clinical, epide-
miological and experimental findings, result in a milder   
form of the disease and are more sensitive to treat-
ment than those found in the Southern Cone below the 
Equator. This may be the result of a lesser exposure to   
benznidazole, which might also favour these differences 
(Devera et al. 2003, Miles et al. 2003).
The time that elapsed between the spraying of infest-
ed dwellings with residual insecticides and the treatment 
enabled us to assume that most of the children were in the 
indeterminate form of the early chronic phase of Chagas 
disease. Therefore, higher and faster seroconversion rates 
in our study cannot be attributed to a short time between 
the infection transmission and the treatment.
Our results clearly demonstrate the efficacy and safe-
ty of a specific treatment program for Chagas disease in 
young children living in endemic areas in Honduras. How-
ever, additional and larger therapeutic trials are needed 
in the country and in the Yoro Department region; these 
studies should include not only clinical results (mortality, 
incidence of sudden death and heart failure) but also in 
vivo and in vitro susceptibility studies of T. cruzi strains.
The information gathered throughout this project has 
produced several important results. First, the study has 
validated, at a local level, a treatment protocol for re-
cent T. cruzi infections among populations in endemic 
rural areas under entomological surveillance where vec-
tor transmission has been interrupted. Second, MSF has 
been able to replicate and implement similar initiatives 
in other countries (including Nicaragua, Guatemala and 
Bolivia). Third, this study offers a starting point for the 
implementation  of  initiatives  to  fight  against  Chagas 
disease in Honduras through close collaborating with 
international institutions like the Japanese International 
Cooperation Agency, the Canadian International Devel-
opment Agency and World Vision. Moreover, serological 
data obtained after treatment will be very useful to epi-
demiological surveillance of the disease in the country.
Finally, this study demonstrates that in areas where 
T. cruzi I is the predominant circulating parasite popula-
tion and where T. cruzi II is responsible for the infection 
in humans, the diagnosis and treatment of Chagas dis-
ease is feasible, necessary and ethically indisputable.
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